ImmunoGen Return On Equity vs. Number Of Shares Shorted

IMGNDelisted Stock  USD 18.20  0.81  4.26%   
Considering ImmunoGen's profitability and operating efficiency indicators, ImmunoGen may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess ImmunoGen's ability to earn profits and add value for shareholders.
For ImmunoGen profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ImmunoGen to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ImmunoGen utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ImmunoGen's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ImmunoGen over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
Please note, there is a significant difference between ImmunoGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmunoGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmunoGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

ImmunoGen Number Of Shares Shorted vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining ImmunoGen's current stock value. Our valuation model uses many indicators to compare ImmunoGen value to that of its competitors to determine the firm's financial worth.
ImmunoGen is rated fourth overall in return on equity category among its peers. It is rated second overall in number of shares shorted category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ImmunoGen's earnings, one of the primary drivers of an investment's value.

ImmunoGen Number Of Shares Shorted vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

ImmunoGen

Return On Equity

 = 

Net Income

Total Equity

 = 
-0.2
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

ImmunoGen

Shares Shorted

 = 

Shorted by Public

+

by Institutions

 = 
20.61 M
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.

ImmunoGen Number Of Shares Shorted Comparison

ImmunoGen is currently under evaluation in number of shares shorted category among its peers.

ImmunoGen Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in ImmunoGen, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ImmunoGen will eventually generate negative long term returns. The profitability progress is the general direction of ImmunoGen's change in net profit over the period of time. It can combine multiple indicators of ImmunoGen, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate therapies to treat cancer. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. Immunogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 106 people.

ImmunoGen Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on ImmunoGen. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ImmunoGen position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ImmunoGen's important profitability drivers and their relationship over time.

Use ImmunoGen in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ImmunoGen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ImmunoGen will appreciate offsetting losses from the drop in the long position's value.

ImmunoGen Pair Trading

ImmunoGen Pair Trading Analysis

The ability to find closely correlated positions to ImmunoGen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ImmunoGen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ImmunoGen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ImmunoGen to buy it.
The correlation of ImmunoGen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ImmunoGen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ImmunoGen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ImmunoGen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your ImmunoGen position

In addition to having ImmunoGen in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Asset Management Thematic Idea Now

Asset Management
Asset Management Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Asset Management theme has 7 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Asset Management Theme or any other thematic opportunities.
View All  Next Launch
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Other Consideration for investing in ImmunoGen Stock

If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
Stocks Directory
Find actively traded stocks across global markets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Content Syndication
Quickly integrate customizable finance content to your own investment portal